{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T05:00:51Z","timestamp":1780376451814,"version":"3.54.1"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This study aimed to identify the frequency and types of peripheral nervous system involvement, associated clinical features, treatment options, and prognosis in patients receiving immune checkpoint inhibitors (ICIs) for the treatment of malignancy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method:<\/jats:title>\n                    <jats:p>This is a retrospective cross-sectional study. We included the data of patients who presented to our electromyography laboratory with neurologic complaints and were using ICIs between January 2019 and August 2024. We retrieved all medical and electrophysiologic records. In patients with multiple examinations, the first appropriate examination was included. Demographic data, oncologic diagnoses, neurologic diagnoses, and medications used were extracted from patient files and are presented here.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>During the study period, we reviewed the records of 31 patients. Seven patients were excluded. The rough prevalence of newly developed neurologic findings attributed to peripheral nervous system involvement after using ICIs was 8%. The most common peripheral complications were sensory or sensory\u2013motor axonal polyneuropathy and myopathy. The most commonly associated medications for these neurologic manifestations were pembrolizumab, nivolumab, and atezolizumab. Nonambulatory patients received immunomodulatory therapy and demonstrated functional improvement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>ICIs have been increasingly used in cancer treatment and can cause immune-related effects. As demonstrated in our study, the most common peripheral nervous system involvement associated with ICIs is axonal polyneuropathy, followed by myopathy. The type of ICI, cancer type, and prior chemotherapeutic treatments the patients previously received may play a role in the occurrence of these neurologic complications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cnd.0000000000000554","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T04:00:42Z","timestamp":1780372842000},"page":"156-165","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Neuroimmune Crosstalk: Peripheral Nervous System Disorders After Immune Checkpoint Inhibitors"],"prefix":"10.1097","volume":"27","author":[{"given":"Ay\u015feg\u00fcl","family":"G\u00fcnd\u00fcz","sequence":"first","affiliation":[{"name":"Department of Neurology, Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Istanbul, T\u00fcrkiye; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merve","family":"\u0130ri\u015f","sequence":"additional","affiliation":[{"name":"Department of Neurology, Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Istanbul, T\u00fcrkiye; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeliha","family":"Birsin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Medical Oncology, Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Istanbul, T\u00fcrkiye."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynep Hande","family":"Turna","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Medical Oncology, Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Istanbul, T\u00fcrkiye."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"\u00d6zg\u00fcro\u011flu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Medical Oncology, Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Istanbul, T\u00fcrkiye."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurten Uzun","family":"Adatepe","sequence":"additional","affiliation":[{"name":"Department of Neurology, Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Istanbul, T\u00fcrkiye; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"R1-20260602","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"R2-20260602","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primer Nat Res"},{"key":"R3-20260602","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (SITC) toxicity management working group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"suppl 2","key":"R4-20260602","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3747\/co.27.5223","article-title":"A review of cancer immunotherapy: from the past, to the present, to the future","volume":"27","author":"Esfahani","year":"2020","journal-title":"Curr Oncol"},{"key":"R5-20260602","doi-asserted-by":"crossref","first-page":"k4226","DOI":"10.1136\/bmj.k4226","article-title":"Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis","volume":"363","author":"Xu","year":"2018","journal-title":"BMJ"},{"key":"R6-20260602","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fonc.2018.00086","article-title":"Anti-PD-1 and antiCTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations","volume":"8","author":"Seidel","year":"2018","journal-title":"Front Oncol"},{"key":"R7-20260602","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41573-021-00259-5","article-title":"Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies","volume":"21","author":"Sullivan","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"R8-20260602","doi-asserted-by":"crossref","first-page":"e253","DOI":"10.1016\/j.lpm.2018.10.009","article-title":"Neuromuscular complications of immune checkpoint inhibitors","volume":"47","author":"Psimaras","year":"2018","journal-title":"Presse Med"},{"key":"R9-20260602","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s11060-021-03695-w","article-title":"Neurotoxicities associated with immune checkpoint inhibitor therapy","volume":"152","author":"Duong","year":"2021","journal-title":"J Neurooncol"},{"key":"R10-20260602","doi-asserted-by":"crossref","first-page":"e2472","DOI":"10.1212\/WNL.0000000000207632","article-title":"Incidence and outcome of neurologic immune-related adverse events associated with immune checkpoint inhibitors in patients with melanoma","volume":"101","author":"Pepys","year":"2023","journal-title":"Neurology"},{"key":"R11-20260602","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"R13-20260602","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann Oncol"},{"key":"R14-20260602","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1007\/s00415-023-11625-1","article-title":"Peripheral nervous system adverse events associated with immune checkpoint inhibitors","volume":"270","author":"Rossi","year":"2023","journal-title":"J Neurol"},{"key":"R15-20260602","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00228-024-03647-z","article-title":"Immune-related serious adverse events with immune checkpoint inhibitors: systematic review and network meta-analysis","volume":"80","author":"Oliveira","year":"2024","journal-title":"Eur J Clin Pharmacol"},{"key":"R16-20260602","doi-asserted-by":"crossref","first-page":"e1093","DOI":"10.1212\/WNL.0000000000008091","article-title":"Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies","volume":"93","author":"Dubey","year":"2019","journal-title":"Neurology"},{"key":"R17-20260602","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11060-020-03687-2","article-title":"Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database","volume":"152","author":"Mikami","year":"2021","journal-title":"J Neurooncol"},{"key":"R18-20260602","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.2174\/1570159X19666201230151224","article-title":"Immune checkpoint inhibitors and neurotoxicity","volume":"19","author":"Zhao","year":"2021","journal-title":"Curr Neuropharmacol"},{"key":"R19-20260602","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.clinph.2019.03.035","article-title":"Electrophysiological findings in immune checkpoint inhibitor-related peripheral neuropathy","volume":"130","author":"Chen","year":"2019","journal-title":"Clin Neurophysiol"},{"key":"R20-20260602","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jcrc.2021.05.020","article-title":"Critically ill patients with severe immune checkpoint inhibitor related neurotoxicity: a multi-center case series","volume":"65","author":"Rajendram","year":"2021","journal-title":"J Crit Care"},{"key":"R21-20260602","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s00415-024-12872-6","article-title":"Differential diagnosis in immune checkpoint inhibitors neurotoxicity","volume":"272","author":"Garcia","year":"2025","journal-title":"J Neurol"}],"container-title":["Journal of Clinical Neuromuscular Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CND.0000000000000554","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T04:00:50Z","timestamp":1780372850000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CND.0000000000000554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/cnd.0000000000000554","relation":{},"ISSN":["1522-0443","1537-1611"],"issn-type":[{"value":"1522-0443","type":"print"},{"value":"1537-1611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]}}}